A genome-wide association study of heparin-induced thrombocyto - penia using an electronic medical record

Summary

Heparin-induced thrombocytopenia (HIT) is an unpredictable, potentially catastrophic adverse effect of heparin treatment resulting from an immune response to platelet factor 4 (PF4)/heparin complexes. No genome-wide evaluations have been performed to identify potential genetic influences on HIT. Here, we performed a genome-wide association study (GWAS) and candidate gene study using HIT cases and controls identified using electronic medical records (EMRs) coupled to a DNA biobank and attempted to replicate GWAS associations in an independent cohort. We subsequently investigated influences of GWAS-associated single nucleotide polymorphisms (SNPs) on PF4/heparin antibodies in non-heparin treated individuals. In a recessive model, we observed significant SNP associations (odds ratio [OR] 18.52; 95% confidence interval [CI] 6.33-54.23; p=3.18×10^-9) with HIT near the T-Cell Death-Associated Gene 8 (TDAG8). These SNPs are in linkage disequilibrium with a missense TDAG8 SNP. TDAG8 SNPs trended toward an association with HIT in replication analysis (OR 5.71; 0.47-69.22; p=0.17), and the missense SNP was associated with PF4/heparin antibody levels and positive PF4/heparin antibodies in non-heparin treated patients (OR 3.09; 1.14-8.13; p=0.02). In the candidate gene study, SNPs at HLA-DRA were nominally associated with HIT (OR 0.25; 0.15-0.44; p=2.06×10^-6). Further study of TDAG8 and HLA-DRA SNPs is warranted to assess their influence on the risk of developing HIT.

Keywords

Pharamacogenetics - heparins - thrombocytopenia

• References

• 1 Warkentin TE, Levine MN, Hirsh J. et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
• 2 Girolami B, Prandoni P, Stefani PM. et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003; 101: 2955-2959.
• 3 Greinacher A, Farner B, Kroll H. et al. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005; 94: 132-135.
• 4 Franchini M. Heparin-induced thrombocytopenia: an update. Thromb J 2005; 03: 14.
• 5 Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a metaanalysis. Blood 2005; 106: 2710-2715.
• 6 Linkins LA, Dans AL, Moores LK. et al. Treatment and prevention of heparininduced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e495S-e530S.
• 7 Watson H, Davidson S, Keeling D. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol 2012; 159: 528-540.
• 8 Cuker A. Heparin-induced thrombocytopenia: present and future. J Thromb Thrombolysis 2011; 31: 353-366.
• 9 Pamela S, Anna Maria L, Elena D. et al. Heparin-induced thrombocytopenia: the role of platelets genetic polymorphisms. Platelets 2013; 24: 362-368.
• 10 Rollin J, Pouplard C, Leroux D. et al. Impact of polymorphisms affecting the ACP1 gene on levels of antibodies against platelet factor 4-heparin complexes. J Thromb Haemost 2013; 11: 1609-1611.
• 11 Rollin J, Pouplard C, Gratacap MP. et al. Polymorphisms of protein tyrosine phosphatase CD148 influence FcgammaRIIA-dependent platelet activation and the risk of heparin-induced thrombocytopenia. Blood 2012; 120: 1309-1316.
• 12 Pouplard C, Cornillet-Lefebvre P, Attaoua R. et al. Interleukin-10 promoter microsatellite polymorphisms influence the immune response to heparin and the risk of heparin-induced thrombocytopenia. Thromb Res 2012; 129: 465-469.
• 13 Gruel Y, Pouplard C, Lasne D. et al. The homozygous FcgammaRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes. Blood 2004; 104: 2791-2793.
• 14 Daly AK, Donaldson PT, Bhatnagar P. et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816-819.
• 15 Mallal S, Phillips E, Carosi G. et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-579.
• 16 Phillips EJ, Mallal SA. HLA-B*1502 screening and toxic effects of carbamazepine. N Engl J Med 2011; 365: 672 author reply 673.
• 17 Selleng S, Greinacher A, Ittermann T. et al. Heparin/PF4 antibodies formation after heparin treatment: temporal aspects and long-term follow-up. Am Heart J 2009; 158: e15.
• 18 Greinacher A, Kohlmann T, Strobel U. et al. The temporal profile of the anti-PF4/heparin immune response. Blood 2009; 113: 4970-4976.
• 19 Warkentin TE, Sheppard JA, Moore JC. et al. Studies of the immune response in heparin-induced thrombocytopenia. Blood 2009; 113: 4963-4969.
• 20 Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-1292.
• 21 Roden DM, Pulley JM, Basford MA. et al. Development of a large-scale deidentified DNA biobank to enable personalized medicine. Clin Pharmacol Ther 2008; 84: 362-369.
• 22 Denny JC, Spickard A, 3rd Johnson KB. et al. Evaluation of a method to identify and categorize section headers in clinical documents. J Am Med Inform Assoc 2009; 16: 806-815.
• 23 Denny JC, Miller RA, Waitman LR. et al. Identifying QT prolongation from ECG impressions using a general-purpose Natural Language Processor. Int J Med Inform 2009; 78: S34-S42.
• 24 Cuker A, Gimotty PA, Crowther MA. et al. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and metaanalysis. Blood 2012; 120: 4160-4167.
• 25 Volzke H, Alte D, Schmidt CO. et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol 2011; 40: 294-307.
• 26 Greinacher A, Holtfreter B, Krauel K. et al. Association of natural anti-platelet factor 4/heparin antibodies with periodontal disease. Blood 2011; 118: 1395-1401.
• 27 Ludemann J, Piek M, Wood WG. et al. [Methods for quality assurance of medical examination in epidemiological field studies: the “Study of Health in Pomerania” (SHIP)]. Gesundheitswesen 2000; 62: 234-243.
• 28 Juhl D, Eichler P, Lubenow N. et al. Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia. Eur J Haematol 2006; 76: 420-426.
• 29 Althaus K, Strobel U, Warkentin TE. et al. Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. Thromb Res 2011; 128: 256-260.
• 30 Zuvich RL, Armstrong LL, Bielinski SJ. et al. Pitfalls of merging GWAS data: lessons learned in the eMERGE network and quality control procedures to maintain high data quality. Genet Epidemiol 2011; 35: 887-898.
• 31 Howie B, Fuchsberger C, Stephens M. et al. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012; 44: 955-959.
• 32 Abecasis GR, Altshuler D, Auton A. et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-1073.
• 33 Pritchard JK, Stephens M, Donnelly P. Inference of population structure using multilocus genotype data. Genetics 2000; 155: 945-959.
• 34 Price AL, Patterson NJ, Plenge RM. et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-909.
• 35 Purcell S, Neale B, Todd-Brown K. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-575.
• 36 Jia X, Han B, Onengut-Gumuscu S. et al. Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One 2013; 08: e64683.
• 37 Choi JW, Lee SY, Choi Y. Identification of a putative G protein-coupled receptor induced during activation-induced apoptosis of T cells. Cell Immunol 1996; 168: 78-84.
• 38 Onozawa Y, Fujita Y, Kuwabara H. et al. Activation of T cell death-associated gene 8 regulates the cytokine production of T cells and macrophages in vitro. Eur J Pharmacol 2012; 683: 325-331.
• 39 Onozawa Y, Komai T, Oda T. Activation of T cell death-associated gene 8 attenuates inflammation by negatively regulating the function of inflammatory cells. Eur J Pharmacol 2011; 654: 315-319.
• 40 Bacsi S, De Palma R, Visentin GP. et al. Complexes of heparin and platelet factor 4 specifically stimulate T cells from patients with heparin-induced thrombocytopenia/thrombosis. Blood 1999; 94: 208-215.
• 41 Fleischer J, Grage-Griebenow E, Kasper B. et al. Platelet factor 4 inhibits proliferation and cytokine release of activated human T cells. J Immunol 2002; 169: 770-777.
• 42 Suvarna S, Rauova L, McCracken EK. et al. PF4/heparin complexes are T celldependent antigens. Blood 2005; 106: 929-931.
• 43 Scheuerer B, Ernst M, Durrbaum-Landmann I. et al. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages. Blood 2000; 95: 1158-1166.
• 44 Paparella D, Micelli M, Favoino B. et al. Anti-heparin-platelet factor 4 antibodies after cardiopulmonary bypass: role of HLA expression. Haematologica 2001; 86: 326-327.
• 45 Harris K, Nguyen P, Van Cott EM. Platelet PlA2 Polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia. Am J Clin Pathol 2008; 129: 282-286.
• 46 Carlsson LE, Lubenow N, Blumentritt C. et al. Platelet receptor and clotting factor polymorphisms as genetic risk factors for thromboembolic complications in heparin-induced thrombocytopenia. Pharmacogenetics 2003; 13: 253-258.